리커너스_베이직

Founded in 2019, LN Robotics originated from a medical robotics research team established in 2012 at Asan Medical Center in Seoul, Korea. The company focuses on developing cutting-edge medical robots that combine advanced technologies such as artificial intelligence, big data, robotics, and biomaterials, and is committed to leading innovation in the medical robotics industry by creating effective and accurate robots for various treatments with the participation of clinical experts.

LN Robotics is upgrading its product AVIAR after the certification of the product in February 2023, and in anticipation of the commercial version entering the Korean market in 2024, LN Robotics will exhibit at KIMES 2024, the largest medical device expo leading the Korean medical industry, to promote the product to medical staff, global medical device distributors as potential partners, and major hospital officials.

LN Robotics considers the KIMES exhibition as a major opportunity to promote the excellence of LN Robotics' medical robotics products, along with its participation in major conferences on cardiovascular interventional procedures, and is preparing for a successful participation in the exhibition through a company-wide preparation process.

AVIAR, which stands for “All-purpose Vascular Intervention Assist Robot,” is a coronary intervention assist robot that acquired KFDA item certification in February, followed by the certification of the next version updated in August last year, and is preparing for domestic commercialization.

The product approved by the Ministry of Food and Drug Safety is a vascular interventional procedure robot that assists in coronary angiography and interventional procedures, and is characterized by expanded maneuverability of procedural tools and unique haptic interface compared to existing overseas competitors. Cardiovascular interventional procedures are procedures to repair blockages or narrowing of the coronary arteries that supply blood to the heart, and due to the variety and complexity of lesions in vascular diseases, they require long experience and proficiency of the operator. LN Robotic's cardiovascular interventional robot implements differentiated technologies such as precise control and haptic technology that expresses the actions of skilled operators as a robotic system, and multi-channel tool control technology that can respond to complex procedures.

In particular, robotics enables various clinical applications such as remote interventional procedures for emergency patients and non-face-to-face interventional procedures to respond to infectious situations, and has the advantage of minimizing radiation exposure to medical staff during interventional procedures.

Currently, more than 3.5 million coronary, peripheral vascular, and neurological interventional procedures are performed by manual methods, but there are limitations such as deviations in procedural accuracy and speed due to the complexity of the procedure, prolonged radiation exposure to medical staff and patients, high learning curve, and lack of skilled medical staff.

Robotic interventional procedures solve many of the problems of traditional manual interventional procedures, leading to greater procedural precision, shorter procedure times, and reduced radiation exposure and contrast use from X-ray-based imaging for medical staff and patients.

LN Robotic plans to enter the domestic market in 2024 by selling products based on innovative medical technology, and for this purpose, medical marketing is underway for domestic specialty hospitals (10 hospitals) and major domestic hospitals (5 hospitals), and a total of more than 3 robotic systems are expected to be sold in 24, and the overseas market can be entered based on the approval of the Korean Food and Drug Administration, and LOIs for product sales with local medical device distributors in Southeast Asia, South America, and Central Asia have been signed with 6 distributors, and at least 1 robotic system can be sold in 25.

In addition, we are planning to develop robots for cerebrovascular and peripheral vascular intervention procedures, starting with cardiovascular intervention robots, and will continue to develop new robot systems that can be utilized in other fields such as pain intervention procedures by utilizing this remote-controlled robot system technology, and furthermore, we aim to become a leading domestic medical robot company and a company that takes the lead in pioneering the global market by developing various robots in the field of medical service robots.

Meanwhile, the upcoming KIMES, which will be held at COEX in Seoul from March 14 to 17, 2024, is the largest medical device and hospital equipment exhibition in Korea, which has grown steadily along with the development of the Korean medical industry since its first edition in 1980. Currently, the Korean medical industry has transformed into a technology-intensive high-tech industry, including medical information systems, ultrasound machines, imaging medical equipment, robotic medicine, AI, and rehabilitation medicine. KIMES is contributing to the advancement of the Korean medical industry and has become a world-class medical exhibition. At the exhibition, exhibitors will showcase new technologies and products in the medical industry, including advanced hospital facilities, medical information systems combined with IT technology, and the automotive industry for rapid patient transportation.

https://kimes.kr/kor/board/kimes_view.asp?B_CODE=TB_NEWS_KR&NUM=688